BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension.
Author
Spikes, Leslie ABajwa, Abubakr A
Burger, Charles D
Desai, Sapna V
Eggert, Michael S
El-Kersh, Karim A
Fisher, Micah R
Johri, Shilpa
Joly, Joanna M
Mehta, Jinesh
Palevsky, Harold I
Ramani, Gautam V
Restrepo-Jaramillo, Ricardo
Sahay, Sandeep
Shah, Trushil G
Deng, Chunqin
Miceli, Melissa
Smith, Peter
Shapiro, Shelley M
Date
2022-04-07Journal
Pulmonary CirculationPublisher
SAGE Publications Inc.Type
Article
Metadata
Show full item recordAbstract
Inhaled treprostinil is an approved therapy for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease in the United States. Studies have confirmed the robust benefits and safety of nebulized inhaled treprostinil, but it requires a time investment for nebulizer preparation, maintenance, and treatment. A small, portable treprostinil dry powder inhaler has been developed for the treatment of PAH. The primary objective of this study was to evaluate the safety and tolerability of treprostinil inhalation powder (TreT) in patients currently treated with treprostinil inhalation solution. Fifty-one patients on a stable dose of treprostinil inhalation solution enrolled and transitioned to TreT at a corresponding dose. Six-minute walk distance (6MWD), device preference and satisfaction (Preference Questionnaire for Inhaled Treprostinil Devices [PQ-ITD]), PAH Symptoms and Impact (PAH-SYMPACT®) questionnaire, and systemic exposure and pharmacokinetics for up to 5 h were assessed at baseline for treprostinil inhalation solution and at Week 3 for TreT. Adverse events (AEs) were consistent with studies of inhaled treprostinil in patients with PAH, and there were no study drug-related serious AEs. Statistically significant improvements occurred in 6MWD, PQ-ITD, and PAH-SYMPACT. Forty-nine patients completed the 3-week treatment phase and all elected to participate in an optional extension phase. These results demonstrate that, in patients with PAH, transition from treprostinil inhalation solution to TreT is safe, well-tolerated, and accompanied by statistically significant improvements in key clinical assessments and patient-reported outcomes with comparable systemic exposure between the two formulations at evaluated doses (trial registration: clinicaltrials.gov identifier: NCT03950739).Rights/Terms
© 2022 United Therapeutics Corporation. United Therapeutics Corporation published by John Wiley & Sons Ltd on behalf of Pulmonary Vascular Research Institute.Identifier to cite or link to this item
http://hdl.handle.net/10713/18796ae974a485f413a2113503eed53cd6c53
10.1002/pul2.12063
Scopus Count
Collections
Related articles
- Pharmacokinetics and tolerability of LIQ861, a novel dry-powder formulation of treprostinil.
- Authors: Roscigno R, Vaughn T, Anderson S, Wargin W, Hunt T, Hill NS
- Issue date: 2020 Oct-Dec
- INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH).
- Authors: Hill NS, Feldman JP, Sahay S, Benza RL, Preston IR, Badesch D, Frantz RP, Patel S, Galloway A, Bull TM, INSPIRE study investigators
- Issue date: 2022 Jul
- Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
- Authors: Frost A, Janmohamed M, Fritz JS, McConnell JW, Poch D, Fortin TA, Miller CE, Chin KM, Fisher M, Eggert M, McEvoy C, Benza RL, Farber HW, Kim NH, Pfister T, Shiraga Y, McLaughlin V
- Issue date: 2019 Jan
- An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension.
- Authors: Zamanian RT, Levine DJ, Bourge RC, De Souza SA, Rosenzweig EB, Alnuaimat H, Burger C, Mathai SC, Leedom N, DeAngelis K, Lim A, De Marco T
- Issue date: 2016 Sep
- Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
- Authors: McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W
- Issue date: 2010 May 4